Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-sponsored clinical trial of DKN-01 in patients with advanced hepatocellular carcinoma (HCC) with activated Wnt signaling.

Trial Profile

An investigator-sponsored clinical trial of DKN-01 in patients with advanced hepatocellular carcinoma (HCC) with activated Wnt signaling.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs DKN 01 (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms DIAL-1
  • Most Recent Events

    • 09 Nov 2018 According to a Leap Therapeutics media release, first patient has been enrolled in this study.
    • 09 Nov 2018 Status changed from planning to recruiting, according to a Leap Therapeutics media release.
    • 23 Feb 2018 According to a Leap Therapeutics media release, enrollment of first patient is anticipated in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top